Loading…
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $32M | $-21M | $-22M | $-14M | -115.6% | 20.3% | - |
| 2024 | $27M | $-24M | $-24M | $-9M | -210.3% | 0.5% | - |
| 2023 | $27M | $-21M | $-21M | $-10M | -94.5% | -4.9% | - |
| 2022 | $28M | $-18M | $-18M | $-11M | -57.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 28.15 | 26.77 | 26.92 | 32.38 |
| Cost Of Revenue | 9.68 | 11.91 | 12.32 | 15.31 |
| Gross Profit | 18.47 | 14.86 | 14.59 | 17.07 |
| Operating Expense | 37.25 | 36.70 | 39.33 | 39.18 |
| Operating Income | -18.78 | -21.84 | -24.74 | -22.11 |
| EBITDA | -18.35 | -21.24 | -23.77 | -20.56 |
| EBIT | -18.78 | -21.84 | -24.74 | -22.11 |
| Pretax Income | -18.29 | -20.71 | -24.05 | -21.64 |
| Net Income | -18.29 | -20.71 | -24.05 | -21.64 |
| Net Income Common Stockholders | -19.64 | -22.06 | -25.35 | -22.91 |
| Total Expenses | 46.92 | 48.61 | 51.66 | 54.49 |
| Interest Income | 0.48 | 1.10 | 0.69 | 0.47 |
| Research And Development | 10.56 | 10.27 | 9.76 | 9.38 |
| Selling General And Administration | 26.69 | 26.43 | 29.57 | 30.29 |
| Normalized EBITDA | -18.35 | -21.24 | -23.77 | -20.56 |
| Normalized Income | -18.29 | -20.71 | -24.05 | -21.64 |
| Basic EPS | -0.26 | -0.27 | -0.30 | -0.25 |
| Diluted EPS | -0.26 | -0.27 | -0.30 | -0.25 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -18.29 | -20.71 | -24.05 | -21.64 |
| Reconciled Depreciation | 0.43 | 0.59 | 0.97 | 1.55 |
| Reconciled Cost Of Revenue | 9.68 | 11.91 | 12.32 | 15.31 |
| Net Interest Income | 0.48 | 1.10 | 0.69 | 0.47 |
| Net Income From Continuing And Discontinued Operation | -18.29 | -20.71 | -24.05 | -21.64 |
| Rent Expense Supplemental | 0 | 0 | 0 | 0 |
| Total Operating Income As Reported | -18.78 | -21.84 | -24.74 | -22.11 |
| Diluted Average Shares | 76.06 | 80.70 | 85.18 | 90.96 |
| Basic Average Shares | 76.06 | 80.70 | 85.18 | 90.96 |
| Diluted NI Availto Com Stockholders | -19.64 | -22.06 | -25.35 | -22.91 |
| Preferred Stock Dividends | 1.34 | 1.34 | 1.31 | 1.27 |
| Net Income Including Noncontrolling Interests | -18.29 | -20.71 | -24.05 | -21.64 |
| Net Income Continuous Operations | -18.29 | -20.71 | -24.05 | -21.64 |
| Other Income Expense | 0 | 0.03 | 0 | 0 |
| Other Non Operating Income Expenses | 0 | 0.03 | 0 | 0 |
| Special Income Charges | 0 | 0 | 0 | 0 |
| Other Special Charges | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0.48 | 1.10 | 0.69 | 0.47 |
| Total Other Finance Cost | -0.48 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.48 | 1.10 | 0.69 | 0.47 |
| Other Operating Expenses | 0 | 0 | 0 | -0.49 |
| Selling And Marketing Expense | 12.32 | 12.38 | 12.37 | 12.44 |
| General And Administrative Expense | 14.36 | 14.05 | 17.20 | 17.85 |
| Other Gand A | 14.36 | 14.05 | 17.20 | 17.85 |
| Operating Revenue | 28.15 | 26.77 | 26.92 | 32.38 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Stereotaxis, Inc.this co. | STXS | $177M | - | 12.91 | -115.6% | -9.48 |
| KORU Medical Systems, Inc. | KRMD | $185M | - | 10.79 | -15.5% | -78.39 |
| Humacyte, Inc. | HUMA | $182M | - | 51.25 | -1313.4% | -1.97 |
| Korro Bio, Inc. | KRRO | $182M | - | 2.31 | -228.0% | -1.81 |
| CVRx, Inc. | CVRX | $181M | - | 4.60 |
| -135.6% |
| -3.08 |
| AirSculpt Technologies, Inc. | AIRS | $179M | - | 1.87 | -13.3% | 32.00 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $176M | - | 0.65 | -50.6% | 0.32 |
| Alpha Teknova, Inc. | TKNO | $173M | - | 2.52 | -25.1% | -17.76 |
| Protalix BioTherapeutics, Inc. | PLX | $171M | - | 3.53 | -13.7% | -36.89 |
| Peer Median | - | - | 3.02 | -37.8% | -2.52 | |